CLINICAL_TRIALS
trial_result
· 2025-08-22
Clinical Trial Update: A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) [Phase 2]
Summary
A Phase 2 study (INFRONT-2) evaluating the safety of long-term AL001 dosing in frontotemporal dementia has completed, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alector Inc. | Conditions: Frontotemporal Dementia | Phase 2 | Status: COMPLETED | Results posted: 2025-08-22